All In MedTech

Device Trial Radar · NCT00624390

Sepraspray™ Laparoscopic Myomectomy Study

A Randomized, Masked Patient, Independent Reviewer, Multi-Center Pilot Study to Evaluate the Feasibility of Sepraspray™ Adhesion Barrier in Laparoscopic Myomectomy

Last checked: Nov 20, 2026Latest source record: Dec 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Nov 2007

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanyNot on our public-company list
Sponsor type
Industry
First posted
Feb 27, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.

Conditions

  • Laparoscopic Myomectomy

Interventions

  • SeprasprayDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety endpoints will include the type and incidence of AEs, vital signs, wound healing, laboratory examinations, and medication usage.Time frame: 30 Days post surgery
  2. Efficacy endpoints are on adhesion formation and will include the success the success criterion for the individual patients as either anterior or posterior uterus free of dense adhesions.Time frame: Until end of study

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Naperville, Illinois

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.